Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 69

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 69
---
 2025, and December 31, 2024, the Company had reserved authorized shares of common stock for future issuance as follows:June 30,2025December 31,2024Outstanding awards under equity incentive plans7,395,0437,789,658Outstanding common stock warrants5,483,5275,483,537Possible future issuances under equity incentive plans6,308,8605,383,165Possible future issuances under employee stock purchase plans1,055,6851,148,012Total common shares reserved for future issuance20,243,11519,804,372

19

Common Stock ActivityThe following table summarizes common stock activity for the three and six months ended June 30, 2025:Shares of Common StockBalance as of January 1, 202553,670,709Common stock issued as compensation to third parties9,306Common stock issued as a result of stock options exercised or released999,338Warrants issued as a result of stock warrants exercised10Balance as of March 31, 202554,679,363Common stock issued as a result of stock options exercised or released312,514Common stock issued as a result of the Employee Stock Purchase Plan92,327Balance as of June 30, 202555,084,204Authorized, Issued, and Outstanding Preferred StockAs of June 30, 2025, and December 31, 2024, the Company had 10,000,000 shares of authorized preferred stock, none of which were designated, issued, or outstanding.Warrants to Purchase Common StockThe Company has issued warrants to purchase common stock to various third parties, of which 5,483,527 remain outstanding as of June 30, 2025, and are immediately exercisable. These warrants qualify as participating securities under ASC Topic 260, Earnings per Share, and are treated as such in the net income (loss) per share calculation (Note J). The Company may be required to redeem these warrants for a cash amount equal to the BSM value of the portion of the warrants to be redeemed.While the warrants are outstanding (but unexercised), the warrant holders will participate in any dividend or other distribution of the Company’s assets to its common stockholders by way of return of capital or otherwise. As of June 30, 2025, 10 of the warrants had been exercised. No warrants had been exercised as of December 31, 2024. The warrants have been evaluated to